Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small Cell Lung Cancer NCI-H446 Cells In Vitro

• Published in: Zhongguo fei ai za zhi 2020-04, Vol.23 (4), p.216-222
• Main Authors: Liu, Chao, Zhang, Hongbing, Li, Yongwen, Zhang, Zihe, Shi, Ruifeng, Xu, Songlin, Zhu, Guangsheng, Wang, Pan, Liu, Hongyu, Chen, Jun
• Format: Article
• Language: Chinese
• Subjects: Antineoplastic Agents - pharmacology; apatinib; Apoptosis; Apoptosis - drug effects; Breast cancer; cci-779; Cell cycle; Cell Line, Tumor; cell migration; Cell Movement - drug effects; Cell Proliferation - drug effects; Dose-Response Relationship, Drug; Drug Interactions; Humans; Lung cancer; lung neoplasms; Lung Neoplasms - pathology; Metastasis; mtor inhibitor; Pyridines - pharmacology; Sirolimus - analogs & derivatives; Sirolimus - pharmacology; Small Cell Lung Carcinoma - pathology; Vascular endothelial growth factor
• ISSN: 1009-3419; 1999-6187
• DOI: 10.3779/j.issn.1009-3419.2020.104.08

Lung cancer is the most common malignancy world-wide. Small cell lung cancer is the deadliest subtype of lung cancer, which features such as rapid growth, early metastasis, and high vascularization. Apatinib is a vascular endothelial growth factor receptor 2 inhibitor independently developed in China, which has a significant inhibition in a variety of solid tumors. The purpose of this study is to investigate the effects of Apatinib alone or Apatinib combined with mammalian target of rapamycin (mTOR) inhibitor, CCI-779, on small cell lung cancer cell line NCI-H446 in vitro. The small cell lung cancer cell line NCI-H446 was grew in vitro. The effects of Apatinib alone or Apatinib combined with CCI-779 on proliferation, apoptosis, cell cycle and migration of NCI-H446 small cell lung cancer cells were detected by CCK8; FACS and transwell assays were also carried out; Western blot assays were used to detect vascular endothelial growth factor and cell cycle related protein expression. CCK8 assays showed that high c